fda bpc-157 status 2026 february FDA's own advisory committee voted 8-6 Thursday. BPC-157, on the compounding list now, for ulcerative colitis. staff bpc-157 human clinical trials evidence

State medical board audits of peptide-prescribing practices have increased in several states

Track the age of your reconstituted solutions carefully

The peptide (though technically considered a small molecule) is a potent fat-burning ergogen that inhibits NNMT (nicotinamide N-methyltransferase) a key player in cellular metabolism and energy homeostasis

The FDA's classification addresses the peptide's amino acid sequence and biological activity, not merely its salt form

An intranasal spray solution of B12, also called Nascobal, with the same indications, was FDA approved in January 2005

At this concentration, a 4mg dose requires a full 2mL injection, which is uncomfortably large and will likely hurt at the injection site